ModuleMD Ranks No. 585 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
GRAND BLANC, Mich., Aug. 13, 2025 /CNW/ -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that ModuleMD ranks No. 585 on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia.
'This recognition is not just about growth—it's about the grit and heart of the clinicians we serve,' said Abhinay Rao, CEO of ModuleMD. 'Every product we build stems from a real conversation with a healthcare hero. This ranking validates our mission to reduce burnout, simplify care delivery, and elevate the joy of practicing medicine.'
This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years.
'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' says Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.'
Methodology
Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.
A Milestone Year of Recognition and Celebration
2025 has been a landmark year for ModuleMD—not only for achieving a spot on the Inc. 5000 list for the first time but also for celebrating 25 years of innovation in specialty healthcare. Earlier this year, ModuleMD proudly marked its silver anniversary at the AAAAI Annual Meeting, where the company unveiled the next generation of its AI-driven solutions and honored its long-standing partnerships with Allergy, Pulmonology, and ENT practices across the country.
This momentum continues as ModuleMD prepares to showcase its full suite of offerings this November at ACAAI 2025, highlighting how its intelligent platforms are transforming workflows, enhancing reimbursement, and reducing provider fatigue.
About ModuleMD
ModuleMD is a healthcare technology company based in Grand Blanc, Michigan, delivering EHR-integrated solutions designed for Allergy, Pulmonology, and ENT practices. Built with clinician insight, ModuleMD combines AI, automation, and specialty-specific tools to streamline care and reduce administrative burden.
Key Solutions:
ModuleMD has been recognized as a G2 High Performer (2022–2025) and a Top 100 Healthcare Technology Company (2023) for its innovation and impact in specialty care. To know more about ModuleMD, visit www.modulemd.com
Media Contact:
Cheryl Fernandes
Director, Digital Marketing
[email protected]
Join the Community.
[ Facebook ]
[ Instagram ]
[ LinkedIn ]
[ YouTube ]
Logo: https://mma.prnewswire.com/media/2637848/Module_MD_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/modulemd-ranks-no-585-on-the-2025-inc-5000-list-of-americas-fastest-growing-private-companies-302524360.html
SOURCE ModuleMD Healthcare Solutions Private Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Asian Growth Stocks With Insider Ownership Expecting Up To 93% Earnings Growth
As Asian markets experience a period of growth, bolstered by strong corporate earnings and resilient economic indicators, investors are increasingly focusing on companies with robust insider ownership. In this environment, stocks that combine high insider stakes with significant expected earnings growth can present compelling opportunities for those seeking to align their interests with company insiders who have a vested interest in the firm's success. Top 10 Growth Companies With High Insider Ownership In Asia Name Insider Ownership Earnings Growth Vuno (KOSDAQ:A338220) 15.6% 109.8% Techwing (KOSDAQ:A089030) 19.1% 68% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Sineng ElectricLtd (SZSE:300827) 36% 25.8% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 24.3% Novoray (SHSE:688300) 23.6% 28.2% M31 Technology (TPEX:6643) 30.8% 95.5% Laopu Gold (SEHK:6181) 35.5% 43% Gold Circuit Electronics (TWSE:2368) 31.4% 32.8% Fulin Precision (SZSE:300432) 12.8% 43.7% Click here to see the full list of 593 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Let's explore several standout options from the results in the screener. RemeGen Simply Wall St Growth Rating: ★★★★★★ Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$40.14 billion. Operations: RemeGen's revenue from biopharmaceutical research, service, production, and sales amounts to approximately CN¥1.91 billion. Insider Ownership: 11.2% Earnings Growth Forecast: 66.3% p.a. RemeGen is experiencing significant growth, with earnings forecasted to grow 66.34% annually and revenue expected to increase by 24.6% per year, outpacing the Hong Kong market. Despite high share price volatility, it trades at a notable discount below its estimated fair value. Recent developments include FDA clearance for clinical trials of RC148 in the US and a global Phase 3 trial for Telitacicept, highlighting its innovative drug pipeline and potential for future expansion in international markets. Unlock comprehensive insights into our analysis of RemeGen stock in this growth report. Our comprehensive valuation report raises the possibility that RemeGen is priced higher than what may be justified by its financials. Anhui Estone Materials TechnologyLtd Simply Wall St Growth Rating: ★★★★★☆ Overview: Anhui Estone Materials Technology Co., Ltd specializes in lithium battery coating, electronic communication functional filling, and low-smoke halogen-free flame-retardant materials in China with a market cap of CN¥5.24 billion. Operations: The company generates revenue of CN¥510.72 million from its specialty chemicals segment. Insider Ownership: 32.8% Earnings Growth Forecast: 60.8% p.a. Anhui Estone Materials Technology Ltd. is projected to see robust expansion, with earnings anticipated to grow 60.8% annually and revenue expected to rise by 23.7% per year, surpassing the Chinese market's growth rates. The company recently turned profitable but faces challenges from large one-off items affecting its financial results. Despite these hurdles, no substantial insider trading activity has been reported in recent months, indicating stability in insider sentiment toward the company's prospects. Click here to discover the nuances of Anhui Estone Materials TechnologyLtd with our detailed analytical future growth report. Our valuation report unveils the possibility Anhui Estone Materials TechnologyLtd's shares may be trading at a premium. Caliway Biopharmaceuticals Simply Wall St Growth Rating: ★★★★★☆ Overview: Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries focus on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$208.61 billion. Operations: Caliway Biopharmaceuticals Co., Ltd. generates revenue through its focus on drug development for aesthetic medicine and chronic inflammation. Insider Ownership: 24.2% Earnings Growth Forecast: 93.8% p.a. Caliway Biopharmaceuticals is experiencing significant growth potential, with revenue forecasted to grow at 89% annually, outpacing the Taiwanese market. The company recently gained recognition by being added to the MSCI Global Standard Index and has initiated pivotal Phase 3 trials for its innovative drug CBL-514. Despite a volatile share price and current lack of meaningful revenue, Caliway's strategic advancements in clinical development position it well for future profitability within three years. Delve into the full analysis future growth report here for a deeper understanding of Caliway Biopharmaceuticals. The valuation report we've compiled suggests that Caliway Biopharmaceuticals' current price could be inflated. Key Takeaways Get an in-depth perspective on all 593 Fast Growing Asian Companies With High Insider Ownership by using our screener here. Curious About Other Options? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SEHK:9995 SHSE:688733 and TWSE:6919. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Parents Urged to Make Kids' Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob
"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ -- In a bold wake-up call to parents everywhere, the team behind the acclaimed Screenagers documentaries and the "Away for the Day" campaign launched its latest national initiative on Tuesday, August 12th in NYC: Screen-Free Sleep, a movement to keep kids' bedrooms device-free at night and restore healthy rest to a generation in crisis. To mark the campaign's debut, New Yorkers were treated to an unexpected sight: an entire flash mob of Steve Jobs lookalikes - black turtlenecks, jeans, and all - took to the streets, handing out "iSleep Pro" kits: sleek, phone-style packaging featuring simple sleep masks as a symbol of unplugged rest. Billed as a "technological bedtime breakthrough," the iSleep Pro kits unveiled the real game-changer: no devices in kids' bedrooms at night - a practice the campaign is calling the seatbelt of our time. The message was clear: parents must wake up to the growing crisis - with phones and screens invading bedtime, children are sleeping less, struggling more, and paying the price with their health, mood, and academic performance. "Sleep is as essential to a child's health as nutrition and exercise,but right now, screens are robbing our kids of it," said Dr. Delaney Ruston, physician, filmmaker, and co-founder of the Screen-Free Sleep campaign. "Our campaign empowers parents to make bedrooms device-free at night, building habits that last through the teen years. By making screen-free sleep the norm, we can give our children the rest they need to thrive." The Alarming Numbers: 1 in 4 tweens sleep with their phone in hand. Kids with devices in their bedroom are 2.3x more likely to feel tired during the day. 51% of teens get fewer than 7 hours of sleep most nights. The Solution: Parents are encouraged to take the pledge at to: Remove all devices - phones, tablets, laptops, smartwatches, gaming devices, even smart speakers - from kids' bedrooms at night. Provide a basic alarm clock to replace phone alarms. Store devices overnight in a secure location (ideally in a parent's bedroom to reduce temptation). Why It Matters: Research shows that simply having a device in the room, even if it's not in use, disrupts kids' sleep. Groundbreaking research shows that sleep deprivation in tweens is associated with MRI-verified disruptions in brain development. A device-free bedroom supports emotional regulation, attention, and school performance. How to Get Involved: Parents can sign the pledge, share the campaign with friends, and bring "iSleep Pro" kits to schools, sports events, and community gatherings to help normalize screen-free sleep - just as seat belts became standard safety practice. Assets & Interviews Available: Flash Mob & Campaign Photos: HERE Available experts: Dr. Delaney Ruston - Physician, filmmaker, founder of Screenagers & Screen-Free Sleep Judith Owens, MD, MPH, expert in pediatric sleep medicine, Boston Children's Hospital Lauren Hale, Phd, Sleep Expert, Renaissance School of Medicine, NY To learn more, visit For additional details or to arrange interviews, please contact kelly@ View original content to download multimedia: SOURCE Screenagers Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
India's Muthoot Finance surges to all-time high on hopes of stronger growth
(Reuters) -Shares of India's Muthoot Finance jumped as much as 11.5% to hit an all-time high on Thursday after robust loan growth cemented investor confidence in the company's ability to sustain industry-leading growth. Muthoot's shares looked set to gain the most since June 2020, and were last up at a record 2,760.80 rupees. On Wednesday, it reported a bigger-than-expected 90% surge in first-quarter profit, aided by a 42% jump in loan assets under management as prices of the precious metal soared. Jefferies analysts raised Muthoot's fiscal 2026 earnings per share estimates by nearly a fifth, citing stronger loan growth and lower credit costs. Analysts at Nuvama said Muthoot's earnings were "substantially better than peers," adding that company is confident of maintaining growth. Muthoot Finance shares were trading up 10.2% as of 9:54 a.m. IST and were the top percentage gainer on the Nifty Financial Services index. At least two analysts upgraded their rating on the "buy" rated stock, while 10 raised their price target, according to data compiled by LSEG. The stock is up about 30% so far this year, outperforming rival IIFL Finance's 9% rise, but trails Manappuram Finance's 40% jump. Sign in to access your portfolio
